Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers

Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific Advisory Board (SAB). Dr Lammers, an entrepreneur in the therapeutic oligonucleotide field, will work together with other members of the Cristal Therapeutics SAB to provide strategic guidance and support the continued development of the Company’s programs, including those focused on oligonucleotide therapeutics.

Cristal Therapeutics is utilizing its proprietary CriPec® technology platform to develop a pipeline of targeted nanomedicines with superior therapeutic profiles. The Company’s lead drug candidate, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several oncology products in preclinical discovery that incorporate therapeutic oligonucleotides. These are designed to overcome the major shortcomings of current oligonucleotide therapies, and are customised to enable the controlled and sustained release of a therapeutic payload at the disease site.

Dr Joost Holthuis, Cristal Therapeutic’s CEO and Co-founder said:

”We are pleased to welcome Paul, who has a deep scientific and clinical understanding of the therapeutic oligonucleotide arena and its market potential, to the Cristal Therapeutics’ SAB. We look forward to working with Paul. His immense expertise and experience will be very valuable as we continue to advance our preclinical oligonucleotide programs towards clinical development and maximize the potential of these therapeutic oligonucleotide modalities.”

Dr Paul Lammers is currently Chief Executive Officer of Mirna Therapeutics. Previously, he served as President of Repros Therapeutics Inc., a biopharmaceutical company, after having served for 6 years as the Chief Medical Officer for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Having worked actively in senior roles across the Pharma and Biotech industries for the past 25 years, Dr Lammers has gained therapeutic experiences in women’s and men’s health, neurodegenerative diseases, metabolic disorders, orphan drug diseases, and oncology. Dr Lammers received a M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.

Other members of Cristal Therapeutics SAB can be found here: (https://cristaltherapeutics.com/about-us/scientific-advisory-board/)

Boiler Plate:

Cristal Therapeutics is a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customised nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.

The Company’s lead product, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several other products in preclinical development targeting cancer and inflammatory diseases.

Cristal Therapeutics is a private company that has raised over Euro 19M to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

  • Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates
  • Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates

 

Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other diseases and iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform.

The initial goal of this partnership is to determine the therapeutic efficacy of targeted drugs using Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators – such as IDO1 and TDO2 – with checkpoint inhibitors. iTeos has an option to license Cristal’s proprietary nanotechnology platform to support the development and commercialization of up to three of its immune tumor-targeting programs.

CriPec®, a proprietary nanotechnology platform, consists of tuneable polymers and biodegradable drug linkers that allow for the rational design and straightforward manufacturing of custom-made nanomedicines. Applying the CriPec® platform – drugs entrapped in CriPec® nanoparticles – results in immuno nanomedicines with a superior product profile as compared to the native drug molecule. CriPec® nanoparticles improve the disposition of thousands of drug molecules per particle and allow the controlled release of these molecules specifically at the target site. This results in an improved therapeutic efficacy and tolerability.

Joost Holthuis, Cristal Therapeutics’ CEO, commented:

“This partnership with iTeos allows us to assess and demonstrate the application of our CriPec® nanoparticles, specifically in the area of novel immuno-oncology therapies. We are focused on applying our nanomedicine platform to several promising oncology indications, some of which will be evaluated for the iTeos’ development pipeline.”

Michel Detheux, , iTeos’ CEO, added:

“We are very pleased to enter into this partnership with an emerging clinical-stage nanomedicine platform company. Cristal has a strong and experienced management team, and has demonstrated the capability to quickly develop valuable therapeutic programs. We look forward to applying their platform to some of our drug candidates. We believe it has particular potential in the evolving area of causing so-called “cold tumors” – which are less responsive to checkpoint inhibitors – to become susceptible to various immuno-oncology therapies.”

About Cristal Therapeutics
Maastricht, The Netherlands based Cristal Therapeutics, is a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform. CriPec® transforms drugs into polymeric nanoparticles via an innovative process. These nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec® nanoparticles has been demonstrated in several preclinical disease models. Cristal Therapeutics’ products in development are primarily aimed at treating patients suffering from cancer but offer also opportunities for the treatment of chronic inflammatory diseases. CriPec® docetaxel is the most advanced product candidate, and is under clinical evaluation for the treatment of solid tumors. For more information please visit www.cristaltherapeutics.com.

About iTeos Therapeutics S.A.
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.

Contacts:

Joost Holthuis, CEO
Cristal Therapeutics
+ 31 43 388 5868
joost.holthuis@cristaltherapeutics.com

Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
michel.detheux@iteostherapeutics.com

For iTeos Therapeutics:

Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
sarah@sternir.com

Jonathan Birt, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
iteos@consilium-comms.com
+44 2 037 095 700

For Cristal Therapeutics:

LifeSpring Life Sciences Communication
Leon Melens
lmelens@lifespring.nl
+31 6 538 16 427

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines.

Edwin obtained an MD, MBA and a PhD degree in Medical Sciences and brings a wealth of knowhow in cancer research in the pharmaceutical industry during a career of over 25 years. As consultant and medical director he supervised over 80 oncology drug development programs and 20 clinical trials. As an employee of midsized and major pharma companies, he gained broad knowledge and expertise in clinical oncology development combining his solid scientific and business background.

Before joining Cristal Therapeutics, Dr. Klumper served as interim-CEO of Dutch SMS-oncology, which he co-founded in 2007. He acted as CMO since the inception of the company until 2013. Prior to SMS-oncology, he served at Nabi Biopharmaceuticals as Vice-President Marketing & Sales Europe, at Amgen as Business Unit Director for The Netherlands, for the UK and as Brand Director Europe, at ASTA Medica as Product Manager, and at start-up Yew Tree Pharmaceuticals as Medical Director. He obtained his PhD as cancer research scientist at VU Academic Medical Center in Amsterdam, the Netherlands.

Joost Holthuis, CEO of Cristal Therapeutics, said:

“We are extremely fortunate to have Edwin joining our leadership team. Edwin will no doubt contribute to the already firm nanomedicine programme of CriPec® docetaxel, as well as help us move forward in our efforts to develop novel proprietary nanomedicines.”

Ongoing clinical trial with CriPec® docetaxel
Cristal Therapeutics did start the phase I clinical study in July 2015 with its lead candidate CriPec® docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres in The Netherlands and in Belgium. The first trial data will be available in the course of Q2 2016.

CriPec® docetaxel successfully passed various pre-clinical studies, demonstrating a significantly improved safety and tolerability profile. Current docetaxel-containing products often have limited efficacy, and prolongation of survival comes with a high incidence of adverse events. This imposes major limitations on the current therapy. CriPec® nanoparticles accumulate more preferentially in tumour tissue followed by sustained release, resulting in a significantly higher CriPec® docetaxel exposure of the tumour, thereby overcoming drawbacks of conventional docetaxel therapies.

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres in The Netherlands and in Belgium. The first trial data will be available in the course of Q2 2016.

Cristal Therapeutics has developed a pioneering approach to transform existing drugs against cancer, like docetaxel, and other diseases, into tailor-made nanoparticles via its proprietary polymeric technology, registered as CriPec®. The CriPec® platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability

Lead candidate
CriPec® docetaxel is Cristal Therapeutics’ lead candidate in development and represents a novel treatment approach of solid tumours. CriPec® docetaxel successfully passed various pre-clinical studies, demonstrating a significantly improved safety and tolerability profile. Current docetaxel-containing products often have limited efficacy, and prolongation of survival comes with a high incidence of adverse events. This imposes major limitations on the current therapy. CriPec® nanoparticles accumulate in tumour tissue, resulting in a significantly higher CriPec® docetaxel exposure of the tumour, thereby overcoming drawbacks of conventional docetaxel therapies.

Trial design
The first phase I trial is run by Dr. Ferry Eskens (Erasmus M.C. Cancer Institute (Rotterdam, the Netherlands) and Prof. Dr. Patrick Schöffski (Department of General Medical Oncology, University Hospitals Leuven, Belgium). The safety, tolerability and pharmacokinetics upon different administered doses will be assessed by monitoring adverse events during the study. This phase I study consists of two parts. In part I the recommended dose will be determined. In part II the efficacy and safety will be evaluated of the recommended dose (as determined in part I).

Joost Holthuis, CEO of Cristal Therapeutics says:

“We are very excited about the start of the clinical phase I trial. The outcome of our pre-clinical program has been very encouraging and highlights the clinical potential of CriPec® docetaxel. We are looking forward to advance this compound quickly into the phase I- part II trial that is expected to start next year. If successful, this will enable chemotherapy to be applied more effectively, with fewer adverse events, which is in the interest of patients with solid tumours worldwide.”

Pipeline growth strategy
The start of this clinical phase I trial in is perfect alignment with Cristal Therapeutics’ strategy focused on the further development of candidates in its pipeline. In addition to forwarding its lead candidate, Cristal Therapeutics is also advancing peptide-based product programs (solid tumours), a dexamethasone based product (inflammation) and an antigen nanomedicine based on Cristal Therapeutics’ CriVac vaccine technology.

Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.

The CriVac® platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac® is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec®.

PX Biosolutions is an Australian based company operating from Melbourne, Victoria.
PX Biosolutions’ scientists have developed DCtag™ vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.

Joost Holthuis, CEO of Cristal Therapeutics says:

“We are very excited about this collaboration that fits our strategy to set up product developments with companies active in the vaccine area. We are convinced that we can create additional value for patients and vaccine companies by development of superior vaccine products based on our CriVac® technology”.

Ann Meulemans, CEO of PX Biosolutions comments:

“Our team is very enthusiastic about the possibility to enhance the flexibility of  its DCtag™ platform by using the CriVac technology“.

 

Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications

Maastricht, The Netherlands, 22 June, 2015 – Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec® platform, today announced the publication of three articles on CriPec®-based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder and CSO of Cristal Therapeutics, and clearly demonstrate the superior therapeutic performance of CriPec® nanomedicines in preclinical models as well as the position of the CriPec® platform in the overall nanotherapeutics field.

In the first publication by Talleli et al. in Nano Today, Dr. Rijcken provides her vision on the translational development of polymeric nanoparticles. Many different micelles have been developed in recent years, and some of them have steadily progressed into clinical evaluation. Increasing evidence suggests that for efficient drug targeting, the micelles need to be stabilised, to prevent premature disintegration. Particularly upon temporarily covalently entrapment of drugs within these nanoparticles (i.e. the CriPec platform), promising efficacy in various animal models has been demonstrated. Recent advances in this field, including tailorable drug release kinetics at the target site as well as potential applications and the clinical development path are described.

The second publication of Hu et al. on CriPec® docetaxel (the lead candidate of Cristal Therapeutics in Biomaterials) describes the complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.
CriPec® docetaxel is a nanoparticle with covalently entrapped docetaxel, designed to have a long blood circulation profile and significantly enhanced tumour accumulation, followed by locally more extended exposure as a result of sustained release of docetaxel over time. In tumour bearing mice, CriPec docetaxel accumulated at least 20 times more in tumour tissue compared to an equivalent dose of the commercially available docetaxel (Taxotere). A superior survival benefit was demonstrated in tumour xenografts and even complete regression has been achieved upon a single administration of CriPec® docetaxel. These remarkable antitumour effects are attributed to the enhanced tumour accumulation and anti-stromal activity. In addition, the preclinical data showed that CriPec® docetaxel exhibited superior tolerability as compared to Taxotere.

In the third publication of Hu et al. in the Journal of Controlled Release article, Dr. Rijcken and colleagues demonstrated the applicability of the CriPec® platform for peptides and the ability to achieve therapeutically relevant blood levels for more than one week upon only a single intravenous injection to rats. Meanwhile, CriPec has also been successfully combined with larger peptides (>30 amino acids).
The transiently stable entrapment of peptides in CriPec® nanoparticles prevents burst release and undesired peak levels, protects peptides against degradation, and enables sustained systemic levels. In addition, since the pharmacokinetic profile of a CriPec nanoparticle is not dependent on the entrapped compound, these CriPec peptide products are also expected to display superior tumour tissue targeting.

“These findings clearly demonstrate the added value of the CriPec® platform, being the improved therapeutic index in oncology for various drug molecules. Relative to the worldwide developments in nanomedicine, the CriPec® platform is really state-of-the-art and capable of translating the biological requirements into a fully tuneable nanomedicine with superior therapeutic outcome.” said Prof. Dr. Twan Lammers, head of the Department of Nanomedicine and Theranostics at RWTH Aachen University Clinic (Germany).

Cristal Therapeutics announces formation of Scientific Advisory Board

Maastricht, The Netherlands, 22 May, 2014 – Cristal Therapeutics, today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni to its new Scientific Advisory Board. Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such as chronic inflammatory disorders, by using its patented CriPec® platform.

Prof. Dr. Rob Liskamp is professor and chair of Chemical Biology and Medicinal Chemistry at the University of Glasgow (Scotland), while maintaining a part-time appointment at Utrecht University as professor of Molecular Medicinal Chemistry. His research interests include synthesis of biologically active peptides and peptide mimics as well as development of protein mimics toward construction of synthetic vaccines and synthetic antibodies.

Prof. Dr. Twan Lammers is professor and head of the department of Nanomedicine and Theranostics at the Institute for Experimental Molecular Imaging at RWTH Aachen University (Germany) and at the Helmholtz Institute for Biomedical Engineering. Since 2012, he has also been appointed at the Department of Targeted Therapeutics at the University of Twente. His primary research interests are drug targeting to tumours, innovative image-guided drug monitoring and tumour-targeted combination therapies. Secondary areas of interest include drug targeting to inflammatory lesions and to the brain, and anatomical, functional and molecular imaging of tumour angiogenesis and metastasis.

Prof. Dr. Alberto Gabizon,  is Professor of Oncology (Shaare Zedek Medical Center, The Hebrew University of Jerusalem), President and founder of LipoMedix Pharmaceuticals and a renowned scientist and clinician in the field of nanomedicine and cancer therapy. His clinical and research contributions in the field of liposomes and targeting therapy of cancers have been recognized by various awards. As co-inventor and co-developer of Doxil®, a smart chemotherapy “drug carrier” with tumor-targeting properties and important safety advantages, Prof. Gabizon is one of the few scientists intimately familiar with the successful development and the clinical implementation of nanomedicinal drugs.

Dr. Maninder Hora, is Senior Vice President, Pharmaceutical Development & Manufacturing Operations of Nektar Therapeutics, headquartered in San Francisco, California,  and Board Member of Nektar India, located in Hyderabad. He is proficient in biologics, small molecules, drug delivery systems and drug-device combination products. He is a key player in the successful registration of 10 drugs and vaccines with the FDA or EMA, and in filing of applications for over 50 unique clinical programs. He has 25+ years of experience in biotechnology and pharmaceutical industry in positions of leadership in research, technical development and corporate governance.

Dr. William Zamboni is associate professor at the Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill. He is also the Director of the Translational Oncology and Nanoparticle Drug Development Initiative Lab. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimisation of the nanoparticulate chemotherapeutic treatment of cancer, including translational development and patient stratification scenarios.

“We welcome the unparalleled clinical and research experience that professors Liskamp, Lammers, Gabizon, Hora and Zamboni bring to the Cristal Therapeutics’ Scientific Advisory Board. Together they represent a major information resource for Cristal Therapeutics, that will play an important role in both our development programs and our plans related to product commercialization as well as licensing and partnership opportunities,” said Cristianne Rijcken, CSO of Cristal Therapeutics.

Recent financing round

In December 2014, Cristal Therapeutics completed a financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed. The financing is used to launch the first clinical study of Cristal Therapeutics’ most advanced therapy, CriPec docetaxel, to be initiated in Q2 2015. If successful, this will enable chemotherapy to proceed more selectively and effectively, with fewer side effects.

Cristal Therapeutics announces appointment of Jeroen Tonnaer as Chief Business Officer

Maastricht, The Netherlands, 21 April, 2015 – Cristal Therapeutics, a privately-held life sciences company developing novel nanotherapeutics against cancer and other diseases, by using its patented CriPec® platform announced today the appointment of Jeroen Tonnaer as new Chief Business Officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities.

Jeroen obtained an MSc in biology, a PhD in pharmacology and is a Certified Licensing Professional (CLP™). As an employee of major pharma companies, he built a broad knowledge and expertise in drug discovery & development and research strategy. He has extensive international and cross-cultural partnering & licensing expertise.

As a neuroscientist Jeroen joined Organon in 1982. He held further positions as Head DMPK, Executive Director Toxicology, and Executive Director Global Research Alliances. Subsequently he was Head Discovery Collaborations Europe for Schering-Plough. Following Schering-Plough’s acquisition by Merck & Co. (called MSD outside the US and Canada), Jeroen joined Merck’s Worldwide Licensing organization in February 2010 to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification and execution of several multimillion-$$ licensing and partnering deals.

“I am delighted to welcome Jeroen to Cristal Therapeutics and look forward to working with him,” remarked CEO Joost Holthuis. “Jeroen will strengthen our key existing business relationships and focus on finding, executing and fostering new partnering opportunities for Cristal Therapeutics.”

Recent financing round

In December 2014, Cristal Therapeutics completed a financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed. The financing is used to launch the first clinical study of Cristal Therapeutics’ most advanced therapy, CriPec docetaxel, to be initiated in Q2 2015. If successful, this will enable chemotherapy to proceed more selectively and effectively, with fewer side effects.

€6 million in new capital and new CEO

Maastricht, The Netherlands, December 15, 2014 – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed. The financing will be used to launch the first clinical study of Cristal Therapeutics’ most advanced therapy, CriPec® docetaxel. Joost Holthuis, co-founder of Cristal Therapeutics and former CEO of OctoPlus, has also been appointed CEO with effect from 1 December.

Cristal Therapeutics develops new therapies against cancer and other diseases, such as chronic inflammatory disorders, by using its patented CriPec technology to entrap existing and new drugs in polymer nanoparticles of 0.0001 mm diameter. These nanoparticles provide better distribution throughout the body and a more selective release of the drugs, such as anti-cancer drugs in the case of tumours. Therefore, products based on CriPec may provide improved efficacy and fewer side effects, offering improved treatment of various diseases.

First clinical study to start in early 2015

In a range of studies performed since 2011, Cristal Therapeutics has demonstrated the safety and efficacy of various CriPec nanomedicines in preclinical studies. In the next few years, the first product, CriPec docetaxel for the treatment of cancer, will be developed further and tested on humans. If successful, this will enable chemotherapy to proceed more selectively and efficiently, with fewer undesirable side effects. Early in 2015, the first clinical study to evaluate CriPec docetaxel will commence.

Dr Joost Holthuis, the new CEO of Cristal Therapeutics, comments on this financing round:
‘Chemelot Ventures joining our group of pre-eminent investors represents a growing commitment to nanomedicine. The continuing commitment and support of our existing investors is extremely important to our business. That commitment reflects the potential of the drug candidates developed by Cristal Therapeutics on the basis of the CriPec technology.’

Marcel Kloosterman, investment manager of Chemelot Ventures:
‘We are impressed by the focus, knowledge and commitment of the Cristal Therapeutics management team. We are pleased to support the company in its efforts to develop a unique new treatment for patients with solid tumours. Cristal Therapeutics’ technology is enabling a more effective use of existing medicines with fewer side effects for the patient and also demonstrates its social relevance. Additionally, Cristal Therapeutics is contributing to a 2 substantial increase in high-grade biopharmaceutical knowledge in our Limburg region in the Netherlands. We look forward to the start of the first clinical study with great confidence.’

Dr Joost Holthuis appointed as CEO

Co-founder Dr Joost Holthuis has succeeded its founder Dr Cristianne Rijcken as CEO of the company, effective since December 1, 2014. Dr Holthuis has an extensive career in the biotech field and founded OctoPlus, which was listed on the Amsterdam stock exchange, and CEO of between 1995 and 2008. In addition to serving on supervisory boards of various highly promising biotech start-ups, Dr Holthuis is also a venture partner at biotech venture capital investor BioGeneration in Naarden.

Dr Rijcken, CEO since its incorporation in 2011, will become Chief Scientific Officer (CSO). Dr Rijcken, together with Joost Holthuis, launched Cristal Therapeutics as a spin-off of the Department of Pharmaceutics of Utrecht University.

Joost Holthuis says:
‘I want to thank Cristianne in particular for her ceaseless commitment to Cristal Therapeutics since our joint start. Her exceptional knowledge and passion for the development of new pharmaceutical therapies will be brought even more to the fore following her appointment as Chief Scientific Officer. I am looking forward to our renewed collaboration in this important period of transformation for Cristal Therapeutics.’